Enzymotec, which develops lipid-based nutritional ingredients and medical foods, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The Migdal Ha'Emeq, Israel-based company, which was founded in 1998 and booked $51 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol ENZY. Enzymotec initially filed confidentially on July 10, 2013. BofA Merrill Lynch and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
